alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › lecanemab

lecanemab

333 studies tagged lecanemab, dated 2000 to 2026-09-09. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. [Antibody therapy in Alzheimer's disease] 2026-09-09
  2. Real-world evidence for amyloid-targeted therapies: Lecanemab and donanemab 2026-08-26
  3. APOE-guided lecanemab dosing dissociates ARIA-E from ARIA-H: The K-ROAD study 2026-08

Studies

333 studies carry this tag.

Date range

2000 to 2026

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 26
  • Journal of Alzheimer's disease : JAD 21
  • The journal of prevention of Alzheimer's disease 20
  • Alzheimer's research & therapy 18
  • Alzheimer's & dementia (New York, N. Y.) 14

148 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2020-11-01 Treatments

    Aducanumab recently underwent two large phase III clinical trials that were stopped prematurely by the sponsor Biogen.

  2. Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019”

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s & Dementia 2020-11-01 Treatments

    The results of the aducanumab studies have not been published in peer-reviewed form and both the analysis presented by Dr Knopman and collaborators and this perspective are based on data presented in 2019 at the Clinical Trials in AD (CTAD) meeting3; both discussions must be seen as tentative until full data are available.

  3. Symptomatic amyloid-related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2020-10-09 Treatments

    Acute symptoms included headache and encephalopathy, and magnetic resonance imaging revealed ARIA-E and ARIA-H. Malignant hypertension and epileptiform activity were treated with nicardipine and levetiracetam.

  4. Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Nature structural & molecular biology 2020-09-28 Treatments

    The amyloid cascade hypothesis, according to which the self-assembly of amyloid-β peptide (Aβ) is a causative process in Alzheimer's disease, has driven many therapeutic efforts for the past 20 years.

  5. Repurposed agents in the Alzheimer's disease drug development pipeline

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Alzheimer's research & therapy 2020-08-17 Drug development

    We identified 53 clinical trials involving 58 FDA-approved agents.

  6. Alzheimer's disease drug development pipeline: 2020

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer's & dementia (New York, N. Y.) 2020-07-16 Drug development

    The 2020 pipeline has innovations in clinical trials and treatment targets that provide hope for greater success in AD drug development programs.

  7. Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Biochemical pharmacology 2020-04-02 Risk factors

    Alzheimer's Disease (AD) therapeutics based on the amyloid hypothesis have repeatedly failed in clinical trials.

  8. The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2020-01-03 Treatments

    Development of disease-modifying treatments for Alzheimer's disease (AD) has been challenging, with no drugs approved to date.

  9. Drug Repositioning for Alzheimer's Disease: Finding Hidden Clues in Old Drugs

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Journal of Alzheimer's disease : JAD 2020 Drug development

    Although more than 100 years have passed since Alois Alzheimer reported a case of Alzheimer's disease (AD), a definitive answer to the causes of cognitive impairment in the disease remains elusive.

  10. Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Journal of Alzheimer's disease : JAD 2020-01-01 Treatments

    Crenezumab doses of ≤120 mg/kg intravenously q4w were well tolerated.

  11. The Future of Anti-Amyloid Trials

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. The journal of prevention of Alzheimer's disease 2020-01-01 Treatments

    The termination of many clinical trials of amyloid-targeting therapies for the treatment of Alzheimer's disease (AD) has had a major impact on the AD clinical research enterprise.

  12. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's research & therapy 2019-12-12 Treatments

    PET amyloid levels were consistent with sparse-to-no neuritic amyloid-β plaques in 51% of patients after 2 years of therapy.

  13. Disease-modifying therapy for proteinopathies: Can the exception become the rule?

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Progress in molecular biology and translational science 2019-08-07 Drug development

    Disease-modifying therapies for proteinopathies are urgently needed yet clinical trials for the major neurodegenerative diseases, Alzheimer's and Parkinson's, have been failing at an alarming rate leaving patients and caregivers scrambling for any sign of hope.

  14. Alzheimer's disease drug development pipeline: 2019

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Alzheimer's & dementia (New York, N. Y.) 2019-07-09 Biomarkers

    Drug development continues robustly at all phases despite setbacks in several programs in the recent past.

  15. Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer's disease: A systematic review and network meta-analysis

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Clinical and investigative medicine. Medecine clinique et experimentale 2019-03-23 Treatments

    In terms of efficacy, the review showed a statistically, but not clinically significant, improvement in favor of immunotherapy versus placebo.

  16. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's research & therapy 2018-11-28 Treatments

    Based on the improved efficacy/safety profile in non-clinical models of SAR228810, a first-in-man single and multiple dose administration clinical study has been initiated in AD patients.

  17. Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia (New York, N. Y.) 2018-11-09 Treatments

    Solanezumab produced statistically significant increases in CSF total Aβ isoforms versus placebo, which correlated with CSF solanezumab concentration.

  18. Multicrossover Randomized Controlled Trial Designs in Alzheimer Disease

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Annals of neurology 2018-08-29 Clinical trials

    Conventional parallel group randomized controlled clinical trials (RCT) in Alzheimer’s disease (AD) are too large, long, expensive and insensitive to clinical change to meet the urgent need for an effective treatment.

  19. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Scientific reports 2018-04-23 Treatments

    Aducanumab, a human-derived antibody targeting amyloid-β (Aβ), is in Phase 3 clinical trials for the treatment of Alzheimer's disease.

  20. Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease (S2.004)

    ✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurology 2018-04-10 Treatments

    In patients treated up to 36 months, amyloid plaque levels continued to decrease in a dose- and time-dependent manner, with levels in the 10 mg/kg fixed-dose group reaching and remaining below a quantitative cut-point discriminating a positive/negative scan. 1 Reduced amyloid plaque levels were also observed in patients switched from placebo to aducanumab during the LTE.

  21. Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Alzheimer's disease : JAD 2018-01-01 Treatments

    Overall, ARIA-E was mild and asymptomatic.

  22. Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study

    ✓ Peer-reviewed alzhub usefulness score 72 out of 100. Journal of Alzheimer's disease : JAD 2018-01-01 Treatments

    Infusion of bapineuzumab 0.5 or 1.0 mg/kg every 13 weeks for up to 3 years was generally well tolerated, with a safety and tolerability profile similar to that in previous studies.

  23. Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study

    ✓ Peer-reviewed alzhub usefulness score 77 out of 100. Current Alzheimer research 2018-01-01 Treatments

    No significant difference was seen in cognitive and functional decline between early and delayed treatment groups.

  24. Efficacy and safety of anti-amyloid- β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Annals of clinical and translational neurology 2017-10-30 Treatments

    To review the optimality and safety of different anti-Amyloid- β (Aβ) immunotherapies for Alzheimer's disease (AD).

  25. The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Expert opinion on biological therapy 2017-10-16 Treatments

    The recent failure of several clinical trials on anti-β-amyloid (Aβ) drugs in Alzheimer's disease (AD) suggested earlier intervention in the disease course.

  26. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Biological psychiatry 2017-08-24 Treatments

    The majority of putative disease-modifying treatments in development for Alzheimer's disease are directed against the amyloid-β (Aβ) peptide.

  27. [DIAN/DIAN-J/DIAN-TU]

    ✓ Peer-reviewed alzhub usefulness score 39 out of 100. Brain and nerve = Shinkei kenkyu no shinpo 2017-07 Risk genes beyond APOE

    The Dominantly Inherited Alzheimer's Network (DIAN) observational study compared pathophysiological markers between mutation carriers and non-carriers in autosomal dominant Alzheimer's disease.

  28. Phase II clinical trials of anti-amyloid β antibodies: When is enough, enough?

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer's & dementia (New York, N. Y.) 2017-05-17 Clinical trials

    Efforts to develop new therapies to combat Alzheimer's disease suffer from extraordinarily high failure rates that make it difficult to justify continued investment in the field.

  29. A phase 3 trial of IV immunoglobulin for Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 76 out of 100. Neurology 2017-04-05 Clinical trials

    No beneficial effects were observed in the dual primary outcome measures for the 2 IVIg doses tested.

  30. Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients

    ✓ Peer-reviewed alzhub usefulness score 78 out of 100. Journal of Alzheimer's disease : JAD 2017-01-01 Treatments

    ARIA was detected more often on MRI scans when every scan was reviewed by trained neuroradiologists and results adjudicated.

  31. Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. The journal of prevention of Alzheimer's disease 2017-01-01 Treatments

    The amyloid hypothesis has been the dominant framework for Alzheimer's disease (AD) research, including the development of anti-AD therapies.

  32. Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis

    ✓ Peer-reviewed alzhub usefulness score 81 out of 100. Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 2016-12-26 Treatments

    Immunotherapeutics targeting amyloid-β (Aβ) have had mixed results in clinical trials.

  33. Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. The Journal of Neuroscience 2016-11-03 Treatments

    Calcium homeostasis plays a major role in maintaining neuronal function under physiological conditions.

  34. Alzheimer's drug-development pipeline: 2016

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer's & dementia (New York, N. Y.) 2016-08-17 Clinical trials

    There are currently 24 agents in 36 trials in phase III of AD drug development.

  35. P2‐003: Clinical Trial Design of Cread: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Study to Evaluate Crenezumab Treatment in Patients with Prodromal‐To‐Mild Alzheimer’s Disease

    ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Alzheimer s & Dementia 2016-07-01 Treatments

    Crenezumab is a humanized anti-amyloid-beta (Aβ) monoclonal IgG4 antibody in development for the treatment of Alzheimer’s disease (AD).

  36. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 53 out of 100. Alzheimer's & dementia (New York, N. Y.) 2016-06-20 Treatments

    In this single-dose study, aducanumab demonstrated an acceptable safety and tolerability profile and linear PK at doses ≤30 mg/kg (clinicaltrials.govNCT01397539).

  37. Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Colloids and surfaces. B, Biointerfaces 2016-04-20 Treatments

    During the last few decades, relevant efforts have been reported to design nanocarriers for drug transport through the blood brain barrier (BBB).

  38. Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody

    ✓ Peer-reviewed alzhub usefulness score 66 out of 100. Alzheimer's research & therapy 2016-04-06 Treatments

    BAN2401 was well-tolerated across all doses.

  39. Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003)

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Neurology 2016-04-05 Treatments

    N/A. ENGAGE and EMERGE are Phase 3 clinical trials designed to confirm the clinical efficacy and safety profile of aducanumab in individuals with Early AD.

  40. Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 62 out of 100. Alzheimer's & dementia (Amsterdam, Netherlands) 2016-03-02 Treatments

    Asymptomatic ARIA-E was detected in solanezumab-treated and placebo-treated AD patients.

  41. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Journal of Alzheimer's disease : JAD 2016-03-01 Treatments

    At the 8th International Conference on Clinical Trials in Alzheimer's Disease held November 5-7, 2015 in Barcelona, Spain, promising data were presented on two candidate Alzheimer's disease immunotherapeutic agents, gantenerumab and aducanumab.

  42. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Alzheimer's research & therapy 2016-03-01 Treatments

    Based on integrated review of laboratory, electrocardiogram, adverse events, and MRI, AAB-003 was safe and well tolerated up to 8 mg/kg for up to 91 weeks (FIH and extension trials) in patients with mild to moderate AD.

  43. [Significance and progress of DIAN/A4/API]

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. Nihon rinsho. Japanese journal of clinical medicine 2016-03 Risk genes beyond APOE

    The DIAN observational study compared the pathophysiological markers between mutation carriers and non-carriers for autosomal dominant Alzheimer's disease.

  44. A Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. The journal of prevention of Alzheimer's disease 2016-01-01 Treatments

    Primary biomarker efficacy endpoints were not statistically significant in either dose group.

  45. Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy

    ✓ Peer-reviewed alzhub usefulness score 40 out of 100. Frontiers in neurology 2015-09-25 Treatments

    Amyloid-related imaging abnormalities (ARIA) represent the major severe side effect of amyloid-beta (Aβ) immunotherapy for Alzheimer's disease (AD).

  46. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

    ✓ Peer-reviewed alzhub usefulness score 70 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2015-08-01 Treatments

    These findings describe solanezumab effects on efficacy/safety measures in a mild AD population.

  47. DT‐01‐03: Efficacy and safety of gantenerumab in prodromal Alzheimer's disease: Results from scarlet road—a global, multicenter trial

    ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer s & Dementia 2015-07-01 Treatments

    SCarlet RoAD (NCT01224106; WN25203), a Phase 3, multicenter, randomized, double-blind, placebo-controlled, 2-year study of gantenerumab in prodromal AD, was the first global registration-enabling study using biomarker screening for entry and a single clinical endpoint for outcome.

  48. O4‐04‐05: Aducanumab (BIIB037), an anti‐amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer's disease: Interim results of a randomized, double‐blind, placebo‐controlled, phase 1b study

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer s & Dementia 2015-07-01 Treatments

    Aducanumab (BIIB037) is a human monoclonal antibody selective for aggregated forms of beta-amyloid peptide being investigated as a disease-modifying treatment for AD.

  49. Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective

    ✓ Peer-reviewed alzhub usefulness score 38 out of 100. The journal of mental health policy and economics 2015-06 Costs and economics

    Adjunctive florbetapir-PET increased quality-adjusted life years (QALYs) by 0.008 years and increased costs by 36 compared to SCE alone (incremental cost-effectiveness ratio [ICER], 4,769).

  50. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 59 out of 100. Alzheimer's research & therapy 2015-04-27 Treatments

    The CAD106 first-in-human study demonstrated a favorable safety profile and promising antibody response.

From across this tag

9 of the 333 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.

All topic tags with their study counts